New combo pill may help diabetes patients control blood sugar

NCT ID NCT06495281

Completed Disease control Sponsor: LG Chem Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed observational study looked at over 2,000 adults with type 2 diabetes who were already taking metformin plus another diabetes drug. Researchers wanted to see if adding a new combination pill called Zemidapa (which contains two diabetes medicines) could improve blood sugar control. The main goal was to measure changes in HbA1c (a long-term blood sugar marker) after 12 weeks. The study also tracked how many patients reached the recommended HbA1c target of below 7%.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zemidapa (a combination of gemigliptin and dapagliflozin) and metformin
What this could lead to: If successful, this could confirm that adding Zemidapa to existing metformin therapy helps more patients reach their blood sugar targets.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only looks at short-term (12-week) effects, and long-term benefits or risks remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Chonnam National University Hwasun Hospital

Hwasun, Jeollanam-do, 58128, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.